The available study linked here does not directly investigate Lactobacillus reuteri for H. pylori support. The single study provided examined cross-reactive antibodies between gut commensal bacteria and SARS-CoV-2, finding a relationship between gut microbiome composition and immune responses to COVID-19 vaccination, which is unrelated to H. pylori or Lactobacillus reuteri specifically. Research does exist elsewhere in the broader scientific literature exploring whether Lactobacillus reuteri may help suppress H. pylori colonization or support eradication therapy outcomes, but that evidence cannot be accurately summarized from the studies provided here. Readers interested in this topic are encouraged to seek out the relevant clinical trial and meta-analysis literature directly, as drawing conclusions from the linked material on this particular question would not be an accurate representation of the evidence.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Pre-existing antibodies targeting a linear epitope on SARS-CoV-2 S2 cross-rea... | Other | 2021 | Neutral | 90 |